Acer Therapeutics Inc., a pharmaceutical company, develops therapies for the treatment of rare diseases with critical unmet medical needs. Its product candidates include Celiprolol for the treatment of vascular Ehlers-Danlos syndrome; and ACER-001 for the treatment of urea cycle disorders and maple syrup urine disease. The company was founded in 2013 and is headquartered in Newton, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ACER
CUSIPN/A
Phone844-902-6100
Debt
Debt-to-Equity RatioN/A
Current Ratio3.26
Quick Ratio3.26
Price-To-Earnings
Trailing P/E Ratio-8.00
Forward P/E Ratio-13.86
P/E GrowthN/A
Sales & Book Value
Annual Sales$2.90 million
Price / Sales103.17
Cash FlowN/A
Price / CashN/A
Book Value$3.03 per share
Price / Book10.16
Profitability
EPS (Most Recent Fiscal Year)($3.84)
Net Income$-14,190,000.00
Net MarginsN/A
Return on Equity-94.75%
Return on Assets-83.40%
Miscellaneous
Employees6
Outstanding Shares9,720,000
Market Cap$281.27 million
Acer Therapeutics (NASDAQ:ACER) Frequently Asked Questions
What is Acer Therapeutics' stock symbol?
Acer Therapeutics trades on the NASDAQ under the ticker symbol "ACER."
How were Acer Therapeutics' earnings last quarter?
Acer Therapeutics Inc (NASDAQ:ACER) released its earnings results on Monday, August, 13th. The biopharmaceutical company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.55) by $0.10. View Acer Therapeutics' Earnings History.
When is Acer Therapeutics' next earnings date?
What price target have analysts set for ACER?
4 equities research analysts have issued 1 year price objectives for Acer Therapeutics' shares. Their forecasts range from $46.00 to $70.00. On average, they expect Acer Therapeutics' stock price to reach $57.00 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.
What is the consensus analysts' recommendation for Acer Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Acer Therapeutics.
Who are some of Acer Therapeutics' key competitors?
Some companies that are related to Acer Therapeutics include Zai Lab (ZLAB), Lexicon Pharmaceuticals (LXRX), Rhythm Pharmaceuticals (RYTM), Karyopharm Therapeutics (KPTI), Intra-Cellular Therapies (ITCI), Omeros (OMER), CytomX Therapeutics (CTMX), Tricida (TCDA), Apellis Pharmaceuticals (APLS), Revance Therapeutics (RVNC), TG Therapeutics Inc common stock (TGTX), Assembly Biosciences (ASMB), Radius Health (RDUS), Amarin (AMRN) and MacroGenics (MGNX).
Who are Acer Therapeutics' key executives?
Acer Therapeutics' management team includes the folowing people:
- Mr. Christopher Schelling, Founder, Pres, CEO & Director (Age 42)
- Mr. Harry S. Palmin, Chief Financial Officer (Age 48)
- Dr. William T. Andrews M.D., FACP, Chief Medical Officer (Age 53)
- Mr. Jefferson Davis, Acting Chief Bus. Officer (Age 51)
- Ms. Kim Tharaldsen, Sr. Director of Marketing
Has Acer Therapeutics been receiving favorable news coverage?
News headlines about ACER stock have been trending positive on Tuesday, according to Accern Sentiment. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Acer Therapeutics earned a daily sentiment score of 0.41 on Accern's scale. They also assigned news coverage about the biopharmaceutical company an impact score of 47.78 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future. View Recent Headlines for Acer Therapeutics.
Who are Acer Therapeutics' major shareholders?
Acer Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Heartland Advisors Inc. (2.05%), Acuta Capital Partners LLC (1.12%) and BlackRock Inc. (0.10%). Company insiders that own Acer Therapeutics stock include Steve Aselage and Timothy C Barabe. View Institutional Ownership Trends for Acer Therapeutics.
Which institutional investors are buying Acer Therapeutics stock?
How do I buy shares of Acer Therapeutics?
Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Acer Therapeutics' stock price today?
One share of ACER stock can currently be purchased for approximately $30.78.
How big of a company is Acer Therapeutics?
Acer Therapeutics has a market capitalization of $281.27 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-14,190,000.00 in net income (profit) each year or ($3.84) on an earnings per share basis. Acer Therapeutics employs 6 workers across the globe.
How can I contact Acer Therapeutics?
Acer Therapeutics' mailing address is 300 WASHINGTON STREET SUITE 351, NEWTON MA, 02458. The biopharmaceutical company can be reached via phone at 844-902-6100 or via email at [email protected]
MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)
MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.
